| Characteristics and Measures . | All subjects (N = 90) . |
|---|---|
| Procedure time, mean (SD), hours | 2.9 ± 1.1 |
| Length of hospital stay, median (IQR), hours | 32.5 (29.0, 54.3) |
| Transferred to ICU post-LITT, n/N (%) | 34/88 (38.6) |
| Discharged to home, No. (%) | 79 (87.8) |
| Total Adverse Events, No. (%) | 17 (18.9) |
| Neurological Deficit | 5 (5.6) |
| Motor | 3 (3.3) |
| Speech aphasia | 1 (1.1) |
| Blurry vision/Visual disturbance/Visual field deficit | 1 (1.1) |
| Seizure—new type/new onset | 1 (1.1) |
| Edema, symptomatic worsening | 2 (2.2) |
| Hemorrhage, clinically significant | 3 (3.3) |
| Hemorrhage, clinically insignificant | 1 (1.1) |
| Cardiac related | 1 (1.1) |
| Deep vein thrombosis | 1 (1.1) |
| Hypoxia | 1 (1.1) |
| Pneumonia | 1 (1.1) |
| Removal of foreign object | 1 (1.1) |
| LITT/surgery-related severe adverse events, no. (%) | 2 (2.2) |
| Characteristics and Measures . | All subjects (N = 90) . |
|---|---|
| Procedure time, mean (SD), hours | 2.9 ± 1.1 |
| Length of hospital stay, median (IQR), hours | 32.5 (29.0, 54.3) |
| Transferred to ICU post-LITT, n/N (%) | 34/88 (38.6) |
| Discharged to home, No. (%) | 79 (87.8) |
| Total Adverse Events, No. (%) | 17 (18.9) |
| Neurological Deficit | 5 (5.6) |
| Motor | 3 (3.3) |
| Speech aphasia | 1 (1.1) |
| Blurry vision/Visual disturbance/Visual field deficit | 1 (1.1) |
| Seizure—new type/new onset | 1 (1.1) |
| Edema, symptomatic worsening | 2 (2.2) |
| Hemorrhage, clinically significant | 3 (3.3) |
| Hemorrhage, clinically insignificant | 1 (1.1) |
| Cardiac related | 1 (1.1) |
| Deep vein thrombosis | 1 (1.1) |
| Hypoxia | 1 (1.1) |
| Pneumonia | 1 (1.1) |
| Removal of foreign object | 1 (1.1) |
| LITT/surgery-related severe adverse events, no. (%) | 2 (2.2) |
| Characteristics and Measures . | All subjects (N = 90) . |
|---|---|
| Procedure time, mean (SD), hours | 2.9 ± 1.1 |
| Length of hospital stay, median (IQR), hours | 32.5 (29.0, 54.3) |
| Transferred to ICU post-LITT, n/N (%) | 34/88 (38.6) |
| Discharged to home, No. (%) | 79 (87.8) |
| Total Adverse Events, No. (%) | 17 (18.9) |
| Neurological Deficit | 5 (5.6) |
| Motor | 3 (3.3) |
| Speech aphasia | 1 (1.1) |
| Blurry vision/Visual disturbance/Visual field deficit | 1 (1.1) |
| Seizure—new type/new onset | 1 (1.1) |
| Edema, symptomatic worsening | 2 (2.2) |
| Hemorrhage, clinically significant | 3 (3.3) |
| Hemorrhage, clinically insignificant | 1 (1.1) |
| Cardiac related | 1 (1.1) |
| Deep vein thrombosis | 1 (1.1) |
| Hypoxia | 1 (1.1) |
| Pneumonia | 1 (1.1) |
| Removal of foreign object | 1 (1.1) |
| LITT/surgery-related severe adverse events, no. (%) | 2 (2.2) |
| Characteristics and Measures . | All subjects (N = 90) . |
|---|---|
| Procedure time, mean (SD), hours | 2.9 ± 1.1 |
| Length of hospital stay, median (IQR), hours | 32.5 (29.0, 54.3) |
| Transferred to ICU post-LITT, n/N (%) | 34/88 (38.6) |
| Discharged to home, No. (%) | 79 (87.8) |
| Total Adverse Events, No. (%) | 17 (18.9) |
| Neurological Deficit | 5 (5.6) |
| Motor | 3 (3.3) |
| Speech aphasia | 1 (1.1) |
| Blurry vision/Visual disturbance/Visual field deficit | 1 (1.1) |
| Seizure—new type/new onset | 1 (1.1) |
| Edema, symptomatic worsening | 2 (2.2) |
| Hemorrhage, clinically significant | 3 (3.3) |
| Hemorrhage, clinically insignificant | 1 (1.1) |
| Cardiac related | 1 (1.1) |
| Deep vein thrombosis | 1 (1.1) |
| Hypoxia | 1 (1.1) |
| Pneumonia | 1 (1.1) |
| Removal of foreign object | 1 (1.1) |
| LITT/surgery-related severe adverse events, no. (%) | 2 (2.2) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
